PolyPid Ltd. (PYPD): Financial results for Q3 2026
PolyPid Ltd. (PYPD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results D-PLEX₁₀₀ NDA Under FDA Priority Review with PDUFA Goal Date of November 28, 2026; U.S. Commercial Launch Preparations Ongoing Expanding D-PLEX₁₀₀ Globally: MAA Submitted and Validated
How this was made
The 30-second read
Why it matters
The earnings release provides new financial metrics and milestone payments, offering traders fresh data to reassess valuation.
Market read
First‑report earnings with regulatory milestones create actionable insight for PYPD traders.
What to watch
Milestone payments are contingent on FDA acceptance; upside may be limited until approval.
PolyPid reports Q3 2026 net loss of $5,754 thousand ($(0.24) per share), down from $7,451 thousand a year earlier, as D-PLEX100 NDA is under FDA Priority Review with PDUFA date of November 28, 2026
The reported net loss narrowed for both the quarter and the nine months, and the company received $30 million from Azurity, including $15 million after quarter end. Research and development expense rose in both periods, the company reports cash, cash equivalents and short-term deposits of $15.5 million, and the filing reports no revenue line. Commercial success depends on FDA approval, which is not yet decided.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expenses, three months ended September 30, 2026GAAP | $6.52M | – | – |
| General and administrative expenses, three months ended September 30, 2026GAAP | $1.53M | – | – |
| Marketing and business development expenses, three months ended September 30, 2026GAAP | $418K | – | – |
| Other income, three months ended September 30, 2026GAAP | $2.55M | – | – |
| Operating loss, three months ended September 30, 2026GAAP | $5.92M | – | – |
| Financial expense (income), net, three months ended September 30, 2026GAAP | −$170K | – | – |
| Loss before income tax, three months ended September 30, 2026GAAP | $5.75M | – | – |
| Income tax expenses, three months ended September 30, 2026GAAP | $2K | – | – |
| Net loss, three months ended September 30, 2026GAAP | $5.75M | – | – |
| Basic and diluted loss per ordinary share, three months ended September 30, 2026GAAP | $(0.24) | – | – |
| Research and development expenses, nine months ended September 30, 2026GAAP | $18.40M | – | – |
| Marketing and business development expenses, nine months ended September 30, 2026GAAP | $1.29M | – | – |
| General and administrative expenses, nine months ended September 30, 2026GAAP | $4.38M | – | – |
| Other income, nine months ended September 30, 2026GAAP | $2.55M | – | – |
| Operating loss, nine months ended September 30, 2026GAAP | $21.53M | – | – |
| Loss on extinguishment of debt, nine months ended September 30, 2026GAAP | $0 thousand (shown as "-") | – | – |
| Financial expense (income), net, nine months ended September 30, 2026GAAP | −$208K | – | – |
| Loss before income tax, nine months ended September 30, 2026GAAP | $21.32M | – | – |
| Income tax expenses, nine months ended September 30, 2026GAAP | $8K | – | – |
| Net loss, nine months ended September 30, 2026GAAP | $21.33M | – | – |
| Basic and diluted loss per ordinary share, nine months ended September 30, 2026GAAP | $(0.94) | – | – |
| Cash, cash equivalents and short-term deposits, as of September 30, 2026other | $15.5M | – | – |
What drove it
- The company states that the increase in research and development expenses was primarily due to ongoing NDA-related activities and continued commercial readiness preparation.
- The company states that the decrease in general and administrative expenses for the quarter was primarily due to lower non-cash expenses related to performance-based options, which vested following the positive Phase 3 SHIELD II topline results.
- The company states that the decrease in nine-month general and administrative expenses was primarily due to lower non-cash performance-based options vesting expenses.
- The company states that other income of $2.5 million reflects the recognition of previously deferred revenue following the termination of the ADVANZ agreement on September 30, 2026.
- The company states that $30 million has been received from Azurity: $15 million upon signing of the agreement in July 2026 and $15 million following FDA acceptance of the NDA, received after September 30, 2026.
- The company states that the EMA validated the D-PLEX100 MAA after quarter end, with a decision expected in the second half of 2027.
- The company states that exclusive European commercialization rights to D-PLEX100 reverted to PolyPid following the mutual termination of the 2022 agreement with ADVANZ PHARMA.
Concerns
- Research and development expense increased to $6,523 thousand in the quarter from $5,257 thousand a year earlier, and to $18,404 thousand for the nine months from $17,589 thousand.
- Cash, cash equivalents and short-term deposits of $15.5 million are reported against a net loss of $21,331 thousand for the nine months.
- The filing reports no revenue line for the quarter or the nine months. The other income line reflects recognition of previously deferred revenue.
- Total shareholders' equity fell to $3,901 thousand as of September 30, 2026 from $10,973 thousand as of December 31, 2025.
- Commercial launch and label expansion depend on FDA decisions, the PDUFA goal date of November 28, 2026, and Azurity's launch execution, which the filing describes as still in preparation.
- Europe commercialization is not yet secured. The company says it is in active discussions with potential partners.
What to watch
- FDA action on the D-PLEX100 NDA by the PDUFA goal date of November 28, 2026.
- Initiation of FDA communications on label expansion of D-PLEX100 into broader abdominal surgery in the fourth quarter of 2026.
- Potential U.S. commercial launch of D-PLEX100 by Azurity in early 2027.
- CMS decision on the NTAP application in August 2027.
- EMA decision on the D-PLEX100 MAA in the second half of 2027.
- Announcement of a European commercial partner for D-PLEX100.
- Timing of the New Drug Submission for D-PLEX100 in Canada, planned for 2027.
- PD01B pre-IND meeting with the FDA and first-in-human study, both expected in the second half of 2027.
- Research and development spending as NDA-related and commercial readiness activities continue.
Balance sheet and cash flow
- Cash, cash equivalents and short-term deposits were $15.5 million as of September 30, 2026, compared with $12.9 million on December 31, 2025. The comparison is with the December 31, 2025 balance, not a prior-year quarter.
- Total assets were $40,120 thousand as of September 30, 2026, compared with $22,307 thousand as of December 31, 2025.
- Accounts receivable were $15,000 thousand as of September 30, 2026, compared with none shown as of December 31, 2025.
- Deferred revenues (non-current) were $30,000 thousand as of September 30, 2026, compared with $2,548 thousand as of December 31, 2025.
- Total shareholders' equity was $3,901 thousand as of September 30, 2026, compared with $10,973 thousand as of December 31, 2025.
- Current maturities of long-term debt were nil as of September 30, 2026, compared with $988 thousand as of December 31, 2025.
- Issued and outstanding ordinary shares were 21,125,704 as of September 30, 2026, compared with 18,204,002 as of December 31, 2025.
- The company received an additional $15 million milestone payment from Azurity after the quarter end, following FDA acceptance of the D-PLEX100 NDA. The company states this will further strengthen its balance sheet.
- The company believes its current cash position, together with expected proceeds from its Azurity commercialization agreement and future potential proceeds, will be sufficient to fund operations into 2028 and through several significant upcoming potential milestones.
Analysis
PolyPid's third-quarter 2026 release reports a GAAP net loss of $5,754 thousand, or $(0.24) per share, against $7,451 thousand, or $(0.37) per share, a year earlier. For the nine months the net loss was $21,331 thousand, or $(0.94) per share, against $25,696 thousand, or $(1.72) per share. Operating loss was $5,922 thousand for the quarter and $21,531 thousand for the nine months, compared with $7,455 thousand and $24,437 thousand in the prior-year periods. The filing reports no revenue line. Its only other income item is $2,548 thousand, which the company says reflects the recognition of previously deferred revenue after the ADVANZ agreement was terminated on September 30, 2026.
The expense mix shifted toward development and launch preparation. Research and development rose to $6,523 thousand in the quarter from $5,257 thousand, and to $18,404 thousand for the nine months from $17,589 thousand. The company attributes the increase to ongoing NDA-related activities and continued commercial readiness preparation. General and administrative expense fell to $1,529 thousand from $1,766 thousand in the quarter and to $4,384 thousand from $5,427 thousand for the nine months. The company explains the decline by lower non-cash expenses for performance-based options, which vested after the Phase 3 SHIELD II topline results. Marketing and business development expense was broadly flat at $418 thousand in the quarter.
The balance sheet shows a shift in the company's funding base. Cash, cash equivalents and short-term deposits were $15.5 million at September 30, 2026, against $12.9 million at December 31, 2025. The company received $30 million from Azurity in total, of which $15 million was recorded as deferred revenue and $15 million arrived after quarter end. Total assets rose to $40,120 thousand from $22,307 thousand, while total shareholders' equity fell to $3,901 thousand from $10,973 thousand. The filing does not include a cash flow statement, so operating and free cash flow are not reported. The company states that its cash position, expected Azurity proceeds and future potential proceeds should fund operations into 2028.
Regulatory and commercial progress is the central subject of the release. The FDA is reviewing the D-PLEX100 NDA under Priority Review with a PDUFA goal date of November 28, 2026, and labeling discussions are underway. Azurity is preparing a U.S. launch in early 2027 and has submitted an NTAP application with a decision expected in August 2027. The EMA validated the MAA after quarter end, and European commercialization rights reverted to PolyPid following the termination of the ADVANZ agreement. The company also introduced PD01B, a Kynatrix-based candidate for diabetic foot infections, which it says will be developed under its own NDA.
The company provides no numerical guidance and no prior outlook was supplied, so no guidance comparison is made. The key figures for the reader are the narrower net loss, the rising research and development expense, the $15.5 million cash balance, and the dependence of the commercial plan on the November 28, 2026 FDA decision. The filing does not state a share repurchase or dividend, and it does not include segment or revenue detail beyond the other income line.
Management, verbatim
With our PDUFA goal date fast approaching, this is a defining moment for PolyPid,
Dikla Czaczkes Akselbrad, Chief Executive Officer, PolyPid
Not in the filing
stated, not guessed- Prior-year and prior-quarter percentage changes are not printed for any metric, so yoy_change and qoq_change are null.
- No prior-year figure is printed for other income, which is shown as a dash for 2025 periods, so prior_year is null for those rows.
- No prior-year or prior-quarter comparison is printed for the balance sheet figures in key_metrics. Comparisons are given only against December 31, 2025, and are listed in balance_sheet_cash_flow.
- Prior-quarter (June 30, 2026) figures are not printed, so prior_quarter is null throughout.
- No revenue line is reported in the filing, so no total revenue or gross margin is available.
- No cash flow statement is included, so operating cash flow and free cash flow are not reported.
- No numerical guidance is given and no prior outlook was supplied, so guidance and vs_prior_guidance are empty.
- No segment or product revenue breakdown is printed.
- No share repurchases or dividends are reported.
- The text figure for the Q3 2026 net loss ($5.8 million) and the table figure ($5,754 thousand) are both printed. The table figure is used in key_metrics.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
PolyPid Ltd., a Nasdaq‑listed biopharma, filed a Form 6‑K reporting its Q3 2026 results and regulatory updates.
Ticker impact
Q3 2026 earnings release showing narrowed net loss to $5.8M, $30M milestone from Azurity, FDA priority review for D‑PLEX100 and EMA filing.
likely upside as investors price in reduced loss and upcoming FDA decision.
First‑report earnings with concrete financials and regulatory milestones provide fresh, material information.
Market effects
Positive signal for biotech sector as FDA priority review may boost peer pipelines.
May support Israeli biotech exposure.
Limited to niche biotech investors.
Counterpoint
Losses remain sizable; regulatory risk could delay commercialization.
Key entities
- companyPolyPid Ltd.
Biopharma company reporting Q3 2026 results.
- partnerAzurity Pharmaceuticals
Partner receiving $30M milestone and preparing U.S. launch.
